Russell Investments Group Ltd. Has $1.89 Million Stake in FibroGen Inc (FGEN)

Russell Investments Group Ltd. lifted its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 360.0% in the third quarter, Holdings Channel reports. The fund owned 31,169 shares of the biopharmaceutical company’s stock after acquiring an additional 24,393 shares during the quarter. Russell Investments Group Ltd.’s holdings in FibroGen were worth $1,894,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Oppenheimer Asset Management Inc. acquired a new stake in FibroGen in the second quarter valued at approximately $236,000. Nisa Investment Advisors LLC grew its stake in FibroGen by 1,829.4% in the third quarter. Nisa Investment Advisors LLC now owns 6,174 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 5,854 shares during the period. Aperio Group LLC grew its stake in FibroGen by 56.3% in the second quarter. Aperio Group LLC now owns 7,004 shares of the biopharmaceutical company’s stock valued at $438,000 after acquiring an additional 2,523 shares during the period. Fox Run Management L.L.C. acquired a new stake in FibroGen in the third quarter valued at approximately $486,000. Finally, Raymond James & Associates grew its stake in FibroGen by 14.2% in the second quarter. Raymond James & Associates now owns 13,174 shares of the biopharmaceutical company’s stock valued at $825,000 after acquiring an additional 1,640 shares during the period. Institutional investors own 64.86% of the company’s stock.

A number of equities research analysts have commented on FGEN shares. Leerink Swann set a $84.00 price objective on FibroGen and gave the company a “buy” rating in a research note on Monday, October 15th. ValuEngine cut FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Zacks Investment Research cut FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. TheStreet cut FibroGen from a “c-” rating to a “d+” rating in a research note on Wednesday, November 21st. Finally, BidaskClub cut FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $72.25.

In related news, CEO Thomas B. Neff sold 39,636 shares of FibroGen stock in a transaction on Wednesday, November 21st. The stock was sold at an average price of $39.37, for a total transaction of $1,560,469.32. Following the sale, the chief executive officer now directly owns 2,676,088 shares in the company, valued at $105,357,584.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jorma Routti sold 6,000 shares of FibroGen stock in a transaction on Monday, September 10th. The stock was sold at an average price of $57.31, for a total value of $343,860.00. Following the sale, the director now owns 137,540 shares in the company, valued at $7,882,417.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 218,673 shares of company stock worth $11,268,878. 8.96% of the stock is owned by insiders.

Shares of NASDAQ:FGEN opened at $41.34 on Wednesday. The company has a market cap of $3.68 billion, a P/E ratio of -23.90 and a beta of 2.13. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.76 and a current ratio of 6.76. FibroGen Inc has a 12-month low of $37.85 and a 12-month high of $68.55.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.15). The company had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $36.48 million. FibroGen had a negative net margin of 87.84% and a negative return on equity of 24.59%. The firm’s revenue for the quarter was down 28.6% compared to the same quarter last year. As a group, research analysts predict that FibroGen Inc will post -1.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Russell Investments Group Ltd. Has $1.89 Million Stake in FibroGen Inc (FGEN)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/12/05/russell-investments-group-ltd-has-1-89-million-stake-in-fibrogen-inc-fgen.html.

FibroGen Profile

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

See Also: Trading Strategy Methods and Types

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply